Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
AssigneeBausch Health Ireland Limited
InventorsLorin K. Johnson, XiaoJun Nicole Deng, William J. Jo Siu, Robert J. Israel, Zeev Heimanson
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to the use of methylnaltrexone, or a salt thereof, and rifaximin for the treatment of increased gut permeability, or an associated disorder, e.g., NASH or NAFLD.
Claims30
A method of treating increased gut permeability, a disease or condition associated with increased gut permeability, and/or reducing gut permeability in a subject in need thereof, the method comprising administering a therapeutic agent selected from the group consisting of methylnaltrexone, or a salt thereof, rifaximin, and a combination thereof.
-3. (canceled)
-7. (canceled)
A method of treating NASH, NAFLD, and/or a symptom thereof in a subject in need thereof, the method comprising administering a therapeutic agent selected from the group consisting of methylnaltrexone, or a salt thereof, rifaximin, and a combination thereof.
(canceled)
-15. (canceled)
(canceled)
A pharmaceutical composition for treating increased gut permeability, treating NASH or a symptom thereof, treating NAFLD or a symptom thereof, treating a disease or condition associated with increased gut permeability, and/or reducing gut permeability in a subject in need thereof, the pharmaceutical composition comprising a therapeutic agent selected from the group consisting of methylnaltrexone, or a salt thereof, rifaximin, and a combination thereof.
-26. (canceled)
-31. (canceled)
(canceled)
Dependencies are inferred from the claim text.